The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
Open accessAbstract
Inflammation plays a central pathogenic role in the pernicious metabolic and end-organ sequelae of obesity. Among these sequelae, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the developed world. The twinned observations that obesity is associated with increased activation of the interleukin (IL)-17 axis and that this axis can regulate liver damage in diverse contexts prompted us to address the role of IL-17RA signaling in the progression of NAFLD. We further examined whether microbe-driven IL-17A regulated NAFLD development and progression. We show here that IL-17RA−/− mice respond to high-fat diet stress with significantly greater weight gain, visceral adiposity, and hepatic steatosis than wild-type controls. However, obesity-driven lipid accumulation was uncoupled from its end-organ consequences in IL-17RA−/− mice, which exhibited decreased steatohepatitis, nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase enzyme expression, and hepatocellular damage. Neutralization of IL-17A significantly reduced obesity-driven hepatocellular damage in wild-type mice. Further, colonization of mice with segmented filamentous bacteria (SFB), a commensal that induces IL-17A production, exacerbated obesity-induced hepatocellular damage. In contrast, SFB depletion protected from obesity-induced hepatocellular damage. Conclusion : These data indicate that obesity-driven activation of the IL-17 axis is central to the development and progression of NAFLD to steatohepatitis and identify the IL-17 pathway as a novel therapeutic target in this condition. (Hepatology 2014;59:1830–1839)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
Effect of In Utero and Early-Life Conditions on Adult Health and Disease
Gluckman, P. D., Hanson, M. A., Cooper, C., & Thornburg, K. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708473 · Cited by 3,898 · cited 1×
“Examples of similar developmental predispositions have been cataloged for other pathophysiologic states.(34) Further, based on our findings, it is a reasonable hypothesis that the classes and/or species of bacteria that drive to hepatocellular damage in human NAFLD likely also induce IL-17.”
BackgroundInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“NAFLD represents a spectrum of disorders that range from nonalcoholic steatosis (NAFL) to nonalcoholic steatohepatitis (NASH) to cirrhosis.(3) In the U.”
BackgroundIvanov, I. I., Frutos, R. D. L., Manel, N., Yoshinaga, K., Rifkin, D. B., Sartor, R. B., Finlay, B. B., & Littman, D. R. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.09.009 · Cited by 1,770
Self-citationFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Insulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191
Ubeda, C., Taur, Y., Jenq, R. R., Equinda, M. J., Son, T., Samstein, M., Viale, A., Socci, N. D., van den Brink, M. R. M., Kamboj, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43918 · Cited by 943
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Cited by
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
IL-17 and IL-17-producing cells in protection versus pathology
Mills, K. H. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00746-9 · Cited by 1,000
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella Pneumoniae
Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., Xue, G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.018 · Cited by 548
Gomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Rau, M., Schilling, A.-K., Meertens, J., Hering, I., Weiss, J., Jurowich, C., Kudlich, T., Hermanns, H. M., Bantel, H., Beyersdorf, N., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501175 · Cited by 302
Mucosal-associated invariant T cells and disease
Toubal, A., Nel, I., Lotersztajn, S., & Lehuen, A. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0191-y · Cited by 300
The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Van Herck, M. A., Weyler, J., Kwanten, W. J., Dirinck, E. L., De Winter, B. Y., Francque, S. M., & Vonghia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00082 · Cited by 238
“Additionally, it has been shown that IL-17 reduces hepatic, muscle and adipose tissue insulin sensitivity (27, 47, 55, 57, 60, 67).”
BackgroundInfluentialLi, F., Hao, X., Chen, Y., Bai, L., Gao, X., Lian, Z., Wei, H., Sun, R., & Tian, Z. (2017) · Nature Communications · doi:10.1038/ncomms13839 · Cited by 191
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
Rolla, S., Alchera, E., Imarisio, C., Bardina, V., Valente, G., Cappello, P., Mombello, C., Follenzi, A., Novelli, F., & Carini, R. (2016) · Clinical Science · doi:10.1042/cs20150405 · Cited by 158
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Self-citationThe Emerging Role of B Cells in the Pathogenesis of NAFLD
Barrow, F., Khan, S., Wang, H., & Revelo, X. S. (2021) · Hepatology · doi:10.1002/hep.31889 · Cited by 126
Giles, D. A., Moreno-Fernandez, M. E., Stankiewicz, T. E., Cappelletti, M., Huppert, S. S., Iwakura, Y., Dong, C., Shanmukhappa, S. K., & Divanovic, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149783 · Cited by 116
Self-citationModeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system
Wang, Y., Wang, H., Deng, P., Tao, T., Liu, H., Wu, S., Chen, W., & Qin, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00682 · Cited by 109
Moreno-Fernandez, M. E., Giles, D. A., Stankiewicz, T. E., Sheridan, R., Karns, R., Cappelletti, M., Lampe, K., Mukherjee, R., Sina, C., Sallese, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93626 · Cited by 106
Self-citationMaricic, I., Marrero, I., Eguchi, A., Nakamura, R., Johnson, C. D., Dasgupta, S., Hernandez, C. D., Nguyen, P. S., Swafford, A. D., Knight, R., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800614 · Cited by 92
γδ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming
Torres‐Hernandez, A., Wang, W., Nikiforov, Y., Tejada, K., Torres, L., Kalabin, A., Adam, S., Wu, J., Lu, L., Chen, R., et al. (2020) · Hepatology · doi:10.1002/hep.30952 · Cited by 80
The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis
Dywicki, J., Buitrago‐Molina, L. E., Noyan, F., Davalos‐Misslitz, A. C., Hupa‐Breier, K. L., Lieber, M., Hapke, M., Schlue, J., Falk, C. S., Raha, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1807 · Cited by 57
Marinović, S., Lenartić, M., Mladenić, K., Šestan, M., Kavazović, I., Benić, A., Krapić, M., Rindlisbacher, L., Cokarić Brdovčak, M., Sparano, C., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1599 · Cited by 43
Functional heterogeneity of CD4+ T cells in liver inflammation
Muscate, F., Woestemeier, A., & Gagliani, N. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00881-w · Cited by 32
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Mechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Feng, D. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.003 · Cited by 18
Choi, M., Chaudhari, H. N., Ji, Y. R., Ryoo, Z. Y., Kim, S. W., & Yun, J. W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2468-1 · Cited by 7
Metadata
- Authors
- Harley, I. T. W., Stankiewicz, T. E., Giles, D. A., Softic, S., Flick, L. M., Cappelletti, M., Sheridan, R., Xanthakos, S. A., Steinbrecher, K. A., Sartor, B. R., Kohli, R., Karp, C. L., & Divanovic, S.
- Venue
- Hepatology
- Published
- 2014-05
- Volume
- 59
- Issue
- 5
- Pages
- 1830-1839
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2009868429
- Cited by
- 250
- References
- 14
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.